Trials / Recruiting
RecruitingNCT03648814
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.
Detailed description
The present study comparing the safety and efficacy of 1.25mg/0.05mL Bevacizumab injection via the intracameral route versus the intravitreal route in treating the neovascular glaucoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Intracameral injection | A/C injection of 1.25 mg/0.05 mL bevacizumab |
| PROCEDURE | Intravitreal injection | Vitreous injection of 1.25 mg/0.05 mL bevacizumab |
Timeline
- Start date
- 2018-08-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2018-08-27
- Last updated
- 2025-08-21
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT03648814. Inclusion in this directory is not an endorsement.